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AtherosclerosisDPP4 is an ubiquitously expressed cell-surface protease that is shedded to the circulation as soluble DPP4 (sDPP4).
We recently identiﬁed sDPP4 as a novel adipokine potentially linking obesity to themetabolic syndrome. The aim
of this study was to investigate direct effects of sDPP4 on human vascular smooth muscle cells (hVSMCs) and to
identify responsible signaling pathways. Using physiological concentrations of sDPP4, we could observe a
concentration-dependent activation of ERK1/2 (3-fold) after 6 h, which remained stable for up to 24 h. Addition-
ally, sDPP4 treatment induced a 1.5-fold phosphorylation of the NF-κB subunit p65. In accordance with sDPP4-
induced stress and inﬂammatory signaling, sDPP4 also stimulates hVSMC proliferation. Furthermore we could
observe an increased expression and secretion of pro-inﬂammatory cytokines like interleukin (IL)-6, IL-8 and
MCP-1 (2.5-, 2.4- and 1.5-fold, respectively) by the sDPP4 treatment. All direct effects of sDPP4 on signaling,
proliferation and inﬂammation could completely be prevented by DPP4 inhibition. Bioinformatic analysis and sig-
naling signature induced by sDPP4 suggest that sDPP4 might be an agonist for PAR2. After the silencing of PAR2,
the sDPP4-induced ERK activation as well as the proliferation was totally abolished. Additionally, the sDPP4-
induced upregulation of IL-6 and IL-8 could completely be prevented by the PAR2 silencing. In conclusion, we
show for the ﬁrst time that sDPP4 directly activates the MAPK and NF-κB signaling cascade involving PAR2 and
resulting in the induction of inﬂammation and proliferation of hVSMC. Thus, our in vitro data might extend the
current view of sDPP4 action and shed light on cardiovascular effects of DPP4-inhibitors.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Type 2 diabetes and obesity are frequently associated with the de-
velopment of cardiovascular disease (CVD) [44]. CVD remains the
major cause of death worldwide and represents a key global health
problem due to the epidemic increase of obesity-induced insulin
resistance and type 2 diabetes [21]. Adipose tissue was long seen as a
passive lipid storage depot but it is now considered as an endo- and
paracrine organ that produces a large number of mediators that affect
metabolism, inﬂammation and coagulation. Expansion of adipose tissue
in obesity is highly associated with an enhanced secretion of pro-
inﬂammatory and pro-atherogenic factors [33,38]. Thus, alterations in
adipocyte derived factors, the so called adipokines, may link obesity to
cardiovascular dysfunction.Integrative Physiology, German
ldorf, Germany. Tel.: +49 211
H. Sell).Dipeptidyl peptidase 4 (DPP4) is an ubiquitously expressed cell-
surface protease, which selectively cleaves N-terminal dipeptides from
a variety of substrates including growth factors, hormones, neuropep-
tides and chemokines. Substantial DPP4 activity is also found in plasma
and other body ﬂuids because of a soluble form of DPP4 lacking the cy-
toplasmic tail and the transmembrane region [28]. In a previous study
we could identify sDPP4 as a novel adipokine [29], which is widely
known for its role in the regulation of glycemia through catabolism of
incretin peptides, and we could show that sDPP4 serum concentrations
positively correlate with various parameters of themetabolic syndrome
like BMI, adipocyte surface, leptin and insulin levels [29,37]. Interesting-
ly, comparison of different fat depots showed the highest DPP4 expres-
sion in visceral adipose tissue of obese patients [37]. Furthermore, we
were the ﬁrst in investigating direct effects of sDPP4 on human adipo-
cytes, human skeletal muscle cells and hVSMC showing a sDPP4-
induced insulin resistance and an increased hVSMC proliferation [29].
Therefore sDPP4 is a promising candidate linking obesity to CVD. Up
to now DPP4 has gained most interest as a therapeutic target for type
2 diabetes treatment due to the degradation of the incretin hormone
glucagon-like peptide (GLP)-1 by this enzyme. Thus, DPP4-inhibitors
are able to prolong the insulinotropic effect of GLP-1 and are now in
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liminary clinical data suggest that DPP4-inhibitors hold interesting
promise for cardiovascular protection. Since GLP-1 itself has favorable
cardiovascular effects [3,32] most of these protective effects of DPP4
inhibition are ascribed to the increased bioavailability of GLP-1. Never-
theless, there are accumulating data suggesting that DPP4-inhibitors
mediate vascular protection independent of GLP-1, involving endotheli-
al repair [19], anti-inﬂammatory effects [15,19,42] and blunting of
ischemic injury [48,49].
Vascular endothelial cells and smooth muscle cells represent the
major cell types of the artery wall preserving vessel wall homeostasis.
Migration of hVSMC from the media to intima and their concomitant
proliferation occurring in the synthetic state are critical causes of arteri-
al wall thickening and the development of arteriosclerosis [27]. More-
over, hVSMCs are involved in the ongoing low-grade inﬂammation
within arteriosclerotic lesions by recruitment of immune cells [9]. How-
ever, the underlying mechanism of hVSMC dysfunction taking place in
type 2 diabetes and obesity is not fully understood.
The aim of the present study was to further investigate direct ef-
fects of sDPP4 on hVSMCs and to identify responsible signaling path-
ways. We report here a novel pathway for sDPP4, involving PAR2-
mediated activation of inﬂammation and proliferation in vitro,
suggesting a potential role of this adipokine in the pathophysiology
of vascular complications.
2. Material and methods
2.1. Cell culture of hVSMC
Primary human coronary artery SMCswere obtained fromPromoCell
(Heidelberg, Germany), tebu-bio (Offenbach, Germany) and Lonza
(Basel, Switzerland). hVSMCs from three different donors (Caucasian,Fig. 1. Effect of sDPP4 on the ERK1/2 signaling pathway in hVSMCs. Cells were serum-starved
concomitant administration of the speciﬁc DPP4-inhibitor K579 for 6 (A and C) and 24 h (B). (A
the phosphorylated form of ERK1/2. Data are tubulin normalizedmean values± SEMof four ind
presented. Two-wayANOVA: sDPP4 p b 0.05, Inhibitor n.s. and sDPP4xInhibitor p b 0.05. (D) hV
for 24 h. Proliferation of hVSMCs was determined by measuring the incorporation of BrdU into
values ± SEM of three independent experiments. *p b 0.05 compared as indicated. Two-way Amale, 58 years old; two female, both 55 years old)were supplied as pro-
liferating cells and kept in culture according to themanufacturer's proto-
col. For all experiments, subconﬂuent cells of passage 5 were used. Cells
were characterized as hVSMCs by morphologic criteria and by immuno-
staining with smooth muscleα-actin. Cells were seeded in smooth mus-
cle cell growth medium (PromoCell, Heidelberg, Germany) with 5% fetal
calf serum (FCS) (Gibco Invitrogen, Carlsbad, CA, USA) and allowed to at-
tach for 24 h. Afterwards cells were serum-starved for 24 h and then ex-
posed to sDPP4 (R&D Systems,Wiesbaden-Nordenstadt, Germany) alone
or in combination with the speciﬁc DPP4-inhibitor K579 (Tocris Biosci-
ence, Bristol, UK), the ERK1/2-inhibitor PD98059 (Calbiochem, Merck
Biosciences, Schwalbach, Germany), the speciﬁc PAR2 antagonist GB83
or the highly speciﬁc IκB-Kinase (IKK)-inhibitor I229 [27]. K579 is a
slow binding but long acting DPP4-inhibitor, whichwas successfully test-
ed as a hypoglycemic agent in Zucker fatty rats [43]. The IKK-inhibitor
was from Sanoﬁ-Aventis (Frankfurt, Germany). It has submicromolar ac-
tivity on the isolated IKK complex and is highly speciﬁc on IKK. The gen-
eral structure of I229 is described in PCT/EP00/05340. TheDPP4- and IKK-
inhibitor were dissolved in DMSO as a 100 mM stock solution, and were
further diluted in sterile serum-free SMCmedium up to 100 nM and 100
μM, respectively. The ERK1/2-inhibitor was already dissolved in DMSO as
a 5 mg/ml stock solution, and was further diluted in sterile serum-free
SMC medium up to 10 μM. Cells were 1 h preincubated with the ERK1/
2- and the IKK-inhibitor and subsequently treated with sDPP4 with and
without concomitant administration of the speciﬁc inhibitors. The specif-
ic PAR2 antagonist GB83 was dissolved in DMSO as a 32.8 mM stock so-
lution and was further diluted in sterile serum-free SMC medium up to
1 μM. All controls of experiments involving the DPP4-, the IKK-inhibitor
or the PAR2 antagonist were treated with DMSO alone. Furthermore,
hVSMCs were treated with the PAR2-activating peptide (AP) (Bachem,
Bubendorf, Switzerland) alone or in combination with PAR2 antagonist
GB83 for 10 min.for 24 h and subsequently treated with the indicated amounts of sDPP4 with and without
–C) Total cell lysates were resolved by SDS-PAGE and immunoblottedwith an antibody to
ependent experiments. *p b 0.05 compared as indicated. RepresentativeWestern Blots are
SMCswere treatedwith sDPP4 alone or in combinationwith the ERK1/2 Inhibitor PD98059
DNA. Data are expressed relative to the basal control value, taken as 100%. Data are mean
NOVA: sDPP4 p b 0.01, Inhibitor p b 0.05 and sDPP4xInhibitor p b 0.01.
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To monitor DNA synthesis, 10.000 hVSMC per 15 mm2 well were
seeded in 96well culture dishes and allowed to attach for 24 h, followed
by serum starvation for an additional 24 h period. hVSMCwere exposed
to sDPP4 alone or in combinationwith the ERK1/2-inhibitor or the PAR2
antagonist in the presence of BrdU (10 μM) for 24 h. All controls of ex-
periments involving ERK1/2-inhibitor or PAR2 antagonist were treated
with DMSO alone. 5% FCS was used as a positive control. The BrdU
ELISA (chemiluminescent) (Roche, Mannheim, Germany) was used to
determine the proliferation according to the manufacturer's protocol.
Signals were visualized and evaluated on a LUMI Imager work station
(Boehringer, Mannheim, Germany).
2.3. Transfection of hVSMC with PAR2 siRNA
To investigate the impact of PAR2 on the sDPP4-induced effects,
hVSMCswere transfectedwith 20 nmol/l sramble siRNA (negative con-
trol) or PAR2 siRNA (Ambion, Life Technologies, Darmstadt, Germany)
using Hiperfect (Qiagen, Venlo, Netherlands) as the transfection re-
agent. 24 h after transfection cells were stimulated with sDPP4 and
then analyzed for BrdU incorporation or lysed for protein or RNA
isolation.
2.4. Analysis of protein expression and phosphorylation
hVSMCs were treated as indicated and lysed in a buffer containing
50 mM HEPES, pH 7.4, 1% TritonX100, complete protease inhibitor and
PhosStop phosphatase inhibitor cocktail. After incubation for 2 h at
4 °C on a rotation-shaker, the suspension was centrifuged at 10,000 gFig. 2. Impact of sDPP4on theNF-κB signaling pathway and the expression of pro-inﬂammatory
amounts of sDPP4 for 6 h. Phosphorylation of the NF-κB subunit p65 was assessed by Weste
experiments. *p b 0.05 compared to control hVSMCs. RepresentativeWestern Blots are presente
of sDPP4 alone or in combination with the IKK-inhibitor I229 for 24 h. mRNA level of IL-6 (B), IL
actin. Data are expressed relative to the basal control value and are means ± SEM of three ind
b 0.05, Inhibitor p b 0.05 and sDPP4xInhibitor n.s.; for C sDPP4 n.s., Inhibitor p b 0.05 and
(E) After 24 h serum-starvation, hVSMCs were exposed to the indicated amounts of sDPP4 fo
tubulin. Representative Western Blot and the respective quantiﬁcation are presented. IL-1β w
are means ± SEM of four independent experiments. *p b 0.05 compared to control hVSMCs.for 15 min. Thereafter, 5 μg protein of lysates were separated by SDS-
PAGE using 10% horizontal gels and transferred to polyvenylidene ﬂuo-
ride ﬁlters in a semi-dry blotting apparatus [45]. Filters were blocked
with Tris-buffered saline containing 0.1% Tween and 5% non-fat dry
milk and subsequently incubated overnight with primary antibodies for
anti-phospho-NF-κB (P65) (Ser536) (Cell Signalling Technology, Frank-
furt, Germany), anti-phospho-p44/42 MAPK (ERK1/2, Thr202/Tyr204)
(Cell Signalling Technology, Frankfurt, Germany), anti-iNOS (BD Trans-
duction Laboratories, Heidelberg, Germany), PAR2 (Santa Cruz Biotech-
nology, Heidelberg, Germany) and alpha-tubulin (Calbiochem Merck
Biosciences, Schwalbach, Germany). After washing, ﬁlters were incubat-
ed with corresponding secondary HRP-coupled antibody (Promega,
Mannheim, Germany) and processed for enhanced chemiluminescence
detection using Immobilon HRP substrate (Millipore, Billerica,
MA, USA). Signals were visualized and evaluated on a LUMI Imager
work station.
2.5. Determination of cytokine secretion
To measure the secretion of pro-inﬂammatory cytokines, superna-
tants were collected after hVSMC were treated for 24 h like indicated.
IL-6, IL-8 and MCP-1 secretion was determined using ELISA kits
purchased from Diaclone (Besancon Cedex, France). The assays were
performed in duplicates according to the manufacturer's instructions.
2.6. RNA isolation, cDNA synthesis and qRT-PCR
To assess the effects on mRNA expression, hVSMCs were harvested
24 h after the addition of sDPP4 with and without the different inhibi-
tors. Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden,cytokines inhVSMCs. (A) After 24h serum-starvation, cellswere treatedwith the indicated
rn Blot analysis. Data are tubulin normalized mean values ± SEM of four independent
d. (B–D) Cells were serum-starved for 24 h and then treatedwith indicated concentrations
-8 (C) and MCP-1 (D) were quantiﬁed by Real-time PCR and normalized to the level of β-
ependent experiments. *p b 0.05 compared as indicated. Two-way ANOVA: for B sDPP4 p
sDPP4xInhibitor p b 0.05; for D sDPP4 p b 0.05, Inhibitor n.s. and sDPP4xInhibitor n.s.
r 18 h. The expression of iNOS was assessed by Western Blot analysis and normalized to
as used as a positive control. Data are expressed relative to the basal control value and
1616 N. Wronkowitz et al. / Biochimica et Biophysica Acta 1842 (2014) 1613–1621Germany) according to themanufacturer's instructions. RNA concentra-
tion andpuritywasmeasuredwith aNanoDrop2000 (ThermoScientiﬁc,
Schwerte, Germany). One microgram of RNA was reversely transcribed
using an Omniscript RT Kit (Qiagen, Venlo, Netherlands). mRNA expres-
sion levels were determinedwith predesigned Quantitect Primer Assays
for IL-6 (QT00083720), IL-8 (QT00000322), MCP-1 (QT00212730) and
β-Actin (QT01680476) and GoTaq® qPCR Master Mix (Promega) on a
StepOne Plus real-time PCR system (Applied Biosystems, Carlsbad, CA,
USA).2.7. Presentation of data and statistics
Data are expressed as mean ± S.E.M. Unpaired two-tailed Student's
t-test or one-way and two-wayANOVA (post hoc test: Bonferroni)were
used to determine statistical signiﬁcance. All statistical analyses were
done using Prism (GraphPad, La Jolla, CA, USA) considering a p-value
b 0.05 as statistically signiﬁcant.Fig. 3.Effect of theDPP4-inhibitor on the sDPP4-induced cytokine expression and secretion. (A)
combination with the DPP4-inhibitor K579 for 6 h. Phosphorylation of the NF-κB subunit p65 w
four independent experiments. *p b 0.05 compared to control hVSMCs. Representative W
sDPP4xInhibitor n.s. (B–D) hVSMC were serum-starved for 24 h and then treated with the ind
mRNA level of IL-6 (B), IL-8 (C) and MCP-1 (D) were quantiﬁed by Real-time PCR and norma
means ± SEM of three independent experiments. *p b 0.05 compared as indicated. Two-w
b 0.05, Inhibitor p b 0.05 and sDPP4xInhibitor = n.s.; for D sDPP4 p b 0.05, Inhibitor p b 0.05
supernatants were collected and IL-6 (E), IL-8 (F) and MCP-1 (G) concentration was measure
SEM of four independent experiments. *p b 0.05 compared as indicated. Two-way ANOVA: fo
and sDPP4xInhibitor p b 0.05; for G sDPP4 p b 0.05, Inhibitor p b 0.05 and sDPP4xInhibitor n.s3. Results
3.1. sDPP4-induced ERK1/2 activation leads to increased proliferation of
hVSMCs
In a previous study, we showed that sDPP4 induces proliferation in
hVSMC in a concentration-dependent manner which can be prevented
by the inhibition of sDPP4 activity [29]. Therefore we investigated the
effects of sDPP4 on the MAPK signaling pathway and its involvement
in hVSMC proliferation. Using increasing concentrations of sDPP4
(2–500 ng/ml), we could observe a concentration-dependent activa-
tion of ERK1/2 (3-fold) after 6 h (Fig. 1A), which remained stable for
up to 24 h (Fig. 1B). To demonstrate the speciﬁcity of this effect,
100 nM of the DPP4-inhibitor K579 was used. The DPP4-inhibitor
alone had no effect, but in combination with sDPP4 the ERK1/2 activa-
tion could be completely abrogated after 6 h (Fig. 1C). Furthermore,
we could show that the sDPP4-induced hVSMC proliferation could to-
tally be prevented by 10 μMof the ERK1/2-inhibitior PD98059 (Fig. 1D).After 24h serum-starvation, cellswere treatedwith indicated amounts of sDPP4 alone or in
as assessed byWestern Blot analysis. Data are tubulin normalized mean values ± SEM of
estern Blots are presented. Two-way ANOVA: sDPP4 p b 0.05, Inhibitor p b 0.05 and
icated amounts of sDPP4 alone or in combination with the DPP4-inhibitor K579 for 24 h.
lized to the level of β-actin. Data are expressed relative to the basal control value and are
ay ANOVA: for B sDPP4 p b 0.01, Inhibitor n.s. and sDPP4xInhibitor n.s.; for C sDPP4 p
and sDPP4xInhibitor p b 0.05. (E–G) After 24 h exposure to the respective treatments,
d by ELISA assay. Data are expressed relative to the basal control value and are means ±
r E sDPP4 n.s., Inhibitor n.s. and sDPP4xInhibitor p b 0.05; for F sDPP4 n.s., Inhibitor n.s.
.
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expression in hVSMCs
To determine whether sDPP4 induces inﬂammation, we analyzed
the impact of sDPP4 on the NF-κB signaling pathway. After 6 h of
sDPP4 treatment we observed a 1.5-fold enhanced phosphorylation of
the NF-κB subunit p-65 (Fig. 2A). Accordingly, we found increased
mRNA levels for the known NF-κB-targets IL-6 (Fig. 2B), IL-8 (Fig. 2C)
and MCP-1 (Fig. 2D) with the most prominent effect for IL-8 (2-fold in-
duction) after 24 h challengewith sDPP4. To conﬁrm the involvement of
NF-κB activation in the sDPP4-induced cytokine expression, we used
the highly speciﬁc IKK-inhibitor I229 in a concentration of 10 μM. As ex-
pected, the IKK-inhibitor itself reduces the basal expression of IL-8 and
MCP-1. Moreover, the elevated expression of the pro-inﬂammatory
cytokines could be completely abolished by IKK inhibition (Fig. 2B–D).
Since it is known that cytokines upregulate iNOS through NF-κB activa-
tion, we tested the impact of sDPP4 on iNOS expression in hVSMCs.
Using increasing concentrations of sDPP4 (20–500 ng/ml), we could ob-
serve a concentration-dependent induction of iNOS (up to 3-fold) after
18 h (Fig. 2E)3.3. DPP4 inhibition completely prevents sDPP4-induced NF-κB activation
and the release of pro-inﬂammatory cytokines
Consistentwith our ﬁndings on the ERK signaling pathway, wewere
able to prevent the sDPP4-induced NF-κB activation after 6 h by the in-
hibition of DPP4 (Fig. 3A), whereas the inhibitor itself showed no effect.
Accordingly, we were also able to block the sDPP4-induced expressionFig. 4. Homology between DPP4 and the tethered ligand (TL) sequence of PAR2. (A) CLUSTA
sequence of PAR2 (SLIGKV). The TL sequence is also aligned to the sequence of the crystallized
crystal structure human DPP4. The potential TL sequence (SLIG) is highlighted in red. Images w(Fig. 3B–D) and secretion (Fig. 3E–G) of the pro-inﬂammatory cytokines
IL-6, IL-8 andMCP-1 byDPP4 inhibition. These data underpin the notion
of incretin-independent effects of DPP4-inhibitors [18].
3.4. DPP4 contains a potential PAR2 activating sequence
The signaling signature induced by sDPP4 suggests that sDPP4might
be an agonist for theprotease-activated receptor family. These receptors
have a unique activationmechanism in that 1) a proteolytically exposed
N-terminal region acts as a tethered ligand (TL) and 2) a peptide, corre-
sponding to the sequence of the TL, can activate the respective receptor
directly. After the alignment of the human DPP4 and the different TL se-
quences for PAR1 (data not shown), PAR2 (Fig. 4A) and PAR4 (data not
shown), we only observed for the TL sequence of PAR2 (SLIGKV) an al-
most perfectmatch of 75% for the ﬁrst four amino acids. It is known that
these four amino acids (SLIG) are the most important for the activation
of PAR2 [1]. The match was found between amino acids 292 and 303 in
the cystein-rich region of DPP4 responsible for partner binding. When
we aligned the potential TL sequence SLIG (in red) with the sequence
of the crystallized DPP4 (in gray), we could locate SLIG on the surface
of DPP4 (Fig. 4B).
3.5. PAR2 silencing prevents sDPP4-induced proliferation and inﬂammation
It could be shown that PAR2 is highly expressed in epithelial cells
and smooth muscle of vascular and nonvascular origins [14]. Here we
assessed PAR2 expression in three different primary human cell types
and observed a 2-time higher PAR2 expression in hVSMC compared toLW was used to align the sequence of the human DPP4 (P27487 UniProtKB) and the TL
DPP4 (PDB ID 4A5S). (B) Surface representation (left) and ribbon diagram (right) of the
ere created with PyMol (PyMOL v1.6).
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(Fig. 5A). To investigate the impact of PAR2 for the sDPP4-induced ef-
fects, we transfected hVSMCs with either 20 nM scramble (negative
control) or PAR2 siRNA. 24 h after the transfection we could observe a
signiﬁcant downregulation of PAR2 mRNA (by 80%) compared to thecontrol situation (Fig. 5B) paralleled by reduced PAR2 protein levels
(Fig. 5C). sDPP4-induced ERK1/2 activation as well as proliferation
could be prevented by PAR2 silencing (Fig. 5D,E) while silencing of
PAR2 itself has no effect on these parameters. In accordance to these
data, sDPP4-induced NF-κB phosphorylation as well as upregulation of
Fig. 6. Impact of the PAR2 antagonist GB83 on sDPP4-inducedERK signaling andproliferation. (A) Cellswere pretreated for 1 hwith the indicated amounts of the PAR2 antagonist and then
stimulatedwith the PAR2-activating peptide (AP) (SLIGKV) for 10min. Phosphorylation of ERK1/2was assessed byWestern Blot analysis. Data are tubulin normalizedmean values± SEM
of three independent experiments. *p b 0.05 compared to control hVSMC. RepresentativeWestern Blot is presented. (B) After 1 h pre-incubationwith the PAR2 antagonist GB83, hVSMCs
were treatedwith sDPP4 for 6 h. Phosphorylation of ERK1/2was assessed byWestern Blot analysis. Data are tubulin normalizedmean values± SEMof three independent experiments. *p
b 0.05 compared as indicated. RepresentativeWestern Blot is presented. Two-way ANOVA: sDPP4 p b 0.05, Antagonist n.s. and sDPP4xAntagonist n.s. (C) Cells were treated for 24 hwith
sDPP4 alone or in combination with the PAR2 antagonist GB83. Proliferation of hVSMCs was determined as described before. Data are expressed relative to the negative control value,
taken as 100%. Data are mean values ± SEM of four independent experiments. *p b 0.05 compared as indicated. Two-way ANOVA: sDPP4 p b 0.05, Antagonist p b 0.001 and
sDPP4xAntagonist p b 0.05.
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sDPP4-induced upregulation of IL-8 could be partially prevented by
PAR2 silencing (Fig. 5H).3.6. The PAR2 antagonist GB83 abrogates sDPP4-induced ERK signaling and
proliferation of hVSMCs
To conﬁrm our silencing data, we also analyzed the effect of the spe-
ciﬁc PAR2 antagonist GB83,which is known toblock the PAR2 activation
both by proteases and the activating peptide (AP) SLIGKV. We could
demonstrate that both 10 and 50 μM of the PAR2 antagonist are able
to block the PAR2-AP-induced ERK signaling after 10 min, whereas the
PAR2 antagonist itself has no effect (Fig. 6A). Using 10 μM of the PAR2
antagonist both sDPP4-induced ERK activation (Fig. 6B) as well as the
proliferation (Fig. 6C) were completely blocked.Fig. 5. Impact of PAR2 silencing on the sDPP4-induced proliferation and inﬂammation. (A) Expr
tiated skeletal muscle cells (SkMC) and adipocytes was assessed by Western Blot. For each cell
mean values ± SEM. *p b 0.05 (n = 3). Representative Western Blots are presented. Cells wer
mRNA levelswere quantiﬁedby Real-time PCR. PAR2mRNAwas normalized to the level ofβ-ac
independent experiments. *p b 0.05 compared to control hVSMC. (C) 30 h after transfection P
presented. (D) 24 h after transfection hVSMCs were exposed to sDPP4 for 6 h. Phosphorylati
values ± SEM of six independent experiments. *p b 0.05 compared as indicated. Representa
sDPP4xSilencing n.s. (E) 24 h after transfection hVSMCs were exposed to sDPP4 for further 24
to the negative control value, taken as 100%. Data aremean values ± SEMof three independent
n.s. and sDPP4xSilencing n.s. (F) 24 h after transfection hVSMCswere exposed to sDPP4 for 6 h. P
mean values ± SEMof three independent experiments. *p b 0.05 compared as indicated. Repres
sDPP4xSilencing p b 0.01. (G and H) 24 h after transfection hVSMCs were exposed to sDPP4 f
normalized to the level of β-actin. Data are expressed relative to the negative control value an
as indicated. Two-way ANOVA: for G sDPP4 n.s., Silencing n.s. and sDPP4xSilencing p b 0.05; fo4. Discussion
Since central obesity is characterized by an enhanced cardiovascular
risk, it has been speculated that adipocyte derived factorsmight directly
contribute to the pathogenesis of atherosclerosis [4,11]. In a previous
study, we identiﬁed sDPP4 as a novel adipokine, which was markedly
higher expressed in and released from visceral compared to subcutane-
ous adipose tissue of obese patients [29,37]. Additionally, we could
demonstrate that sDPP4 directly impairs insulin signaling in three dif-
ferent primary cell types, namely, adipocytes, skeletal muscle, and
smooth muscle cells and increases hVSMC proliferation [29]. Here we
further assessed direct effects of sDPP4 on hVSMC in vitro and aimed
to identify the underlying signaling pathway for the observed inﬂam-
mation and proliferation. For our study, we used sDPP4 concentrations
reﬂecting circulating levels that were measured in both lean and
obese subjects [29]. Interestingly, high serum levels of sDPP4 haveession of PAR2 in three different primary human cell types, namely SMC, in vitro differen-
type three different donors were analyzed. Data are tubulin normalized and expressed as
e transfected either with 20 nM scramble or PAR2 siRNA. (B) 24 h after transfection PAR2
tin. Data are expressed relative to the negative control value and aremeans ± SEMof three
AR2 protein level was assesed by Western Blot analysis. Representative Western Blot is
on of ERK1/2 was detected by Western Blot analysis. Data are tubulin normalized mean
tive Western Blots are presented. Two-way ANOVA: sDPP4 p b 0.05, Silencing n.s. and
h. Proliferation of hVSMC was determined as described before. Data are expressed relative
experiments. *p b 0.05 compared as indicated. Two-way ANOVA: sDPP4 p b 0.05, Silencing
hosphorylation of p65was assessed byWestern Blot analysis. Data are tubulin normalized
entativeWestern Blots are presented. Two-way ANOVA: sDPP4 n.s., Silencing p b 0.05 and
or further 24 h. IL-6 (G) and IL-8 (H) mRNA levels were quantiﬁed by Real-time PCR and
d are means ± SEM of three independent experiments. *p b 0.05, ***p b0,001 compared
r H sDPP4 p b 0.001, Silencing p b 0.01 and sDPP4xSilencing p b 0.05.
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In the present study, we could show that sDPP4 activates theMAPK and
NF-κB signaling cascade resulting in pro-atherogenic changes in hVSMC
illustrated by an increased proliferation, the induction of iNOS and ele-
vated expression and secretion of pro-inﬂammatory cytokines.
DPP4-inhibitors, a class of oral anti-hyperglycemic agents that pro-
long the bioavailability of the endogenously secreted incretin hormone
GLP-1 and the glucose-dependent insulinotropic polypeptide (GIP), are
effective in the treatment of type 2 diabetes. DPP4-inhibitors have been
validated and approved as drugs that can lower both fasting and post-
prandial glucose levels and improve islet β-cell function in patients
with diabetes [16]. In addition to their anti-diabetic properties, accumu-
lating data indicate that DPP4-inhibitors also have important protective
effects on the cardiovascular system. Several meta-analyses mainly
using phase 3 trials repeatedly demonstrated beneﬁcial cardiovascular
effects of DPP4-inhibitors [25,31,34]. However, a very recently pub-
lished clinical trial using the DPP4-inhibitor saxagliptin in type 2 diabet-
ic patients with prior cardiovascular diseases revealed the safety of the
compoundwithout additional cardiovascular beneﬁts [36].Most cardio-
vascular endpoints studied in the trial were not modiﬁed by saxagliptin
but hospitalization due to heart failure was signiﬁcantly higher in the
group treated with the DPP4-inhibitor. As sDPP4 is an adipokine up-
regulated in obesity and type 2 diabetes that triggers insulin resistance
and metabolic complications [29,37], it might be speculated that the
beneﬁcial effects of DPP4-inhibitors would be higher in those early
phases of the metabolic disorders previous to the development of
established cardiovascular disease. Thiswould be a possible explanation
for the lack of positive results in the study by Scirca and collaborators
[29,37]. However, several clinical trials with different DPP4-inhibitors
and deﬁned cardiovascular endpoints (Carolina, TECOS, Prediab) are
still ongoing and will help to clarify safety and cardioprotective effects
in type 2 diabetes patients with and without prior cardiovascular
events. Studies in animals have already shown that DPP4-inhibitors
exert cardiovascular protective effects. In mice and pigs, DPP4-
inhibitors decrease myocardial infarct size, stabilize the cardiac electro-
physiological state during myocardial ischemia, reduce ischemia/
reperfusion injury, and prevent left ventricular remodeling following
myocardial infarction [13,46]. Furthermore, in ApoE−/−mice fed with
a high fat diet the DPP4-inhibitor sitagliptin reduces atherosclerosis le-
sion formation and improves endothelial dysfunction [30]. Additionally,
in LDLR−/− mice DPP4 inhibition prevents monocyte activation and
chemotaxis, thereby reducing aortic plaque formation [39]. Most of
these effects could be ascribed to the increased bioavailability of DPP4
substrates like GLP-1 [5,6], stromal derived factor (SDF)-1α [19,47] or
brain natriuretic peptide (BNP) BNP [7,8]. But despite of the classical
view of DPP4 acting only as an exopeptidase degrading numerous pep-
tide substrates accumulating data suggest that DPP4-inhibitors exert
vascular protective effects also independent of DPP4 substrates. Ta
et al. [42] could demonstrate that the speciﬁc DPP4-inhibitor alogliptin
blocked LPS-induced ERK phosphorylation in U937 histiocytes,
representing a model of cells involved in the progression of atheroscle-
rosis, such as foam cells. Downstream of ERK, the inhibition of DPP4
prevented the activation of matrix metalloproteinases (MMP) via the
Toll-like receptor pathway, which contributes to the destabilization of
atherosclerotic plaques leading to acute vascular events. Whether the
observed effects could be ascribed to direct effects of sDPP4 or to inhibi-
tion of enzymatic degradation of DPP4 substrates remained unknown.
Furthermore, it could be demonstrated that sitagliptin prevents TNFα-
induced PAI-1, ICAM and VCAMgene and protein expression in vascular
endothelial cells independent of GLP-1 [23]. This effect could partially
be explained by a reduction of the TNFα-induced NF-κB mRNA expres-
sion by sitagliptin. Additionally, incubation of human umbilical vein en-
dothelial cells with the DPP4-inhibitor alogliptin resulted in endothelial
nitric oxide synthase (eNOS) and Akt phosphorylation (Ser1177 and
Ser473, respectively) paralleled by a rapid increase in nitric oxide [40].
These data suggest that DPP4 inhibition might play a pivotal role inprevention of endothelial dysfunction. Nevertheless, direct effects of
sDPP4 were not taken into consideration in most of these studies. In a
recently published study, a sDPP4-induced short-term activation of
ERK1/2 in rat VSMC was observed, which could partially be blocked by
DPP4 inhibition [17]. In the same study, the authors also demonstrate
decreased SMC proliferation in vessels of ApoE knockout mice treated
with anagliptin for 16 weeks. However, here we observed a very robust
and long-lasting ERK1/2 activation, which can completely be prevented
by DPP4 inhibition. Moreover, by using an ERK1/2-inhibitor, we could
conﬁrm that the sDPP4-induced proliferation is ERK-dependent. Thus,
our data strongly support a direct role for sDPP4 in regulating vascular
function independently of GLP-1.
Furthermore, our data on the direct effects of sDPP4 suggest that PAR2
is involved in signaling induced by sDPP4. In the literature, it is currently
discussed that ﬁbronectin [12], TLR4 [42] and mannose-6-phosphate re-
ceptor/IGFII receptor [24] may bind DPP4. Bioinformatic analysis and
the signaling signature induced by sDPP4 suggest that sDPP4 might be
an agonist for PAR2. PAR2 is activated by proteolytic cleavage of its N-
terminus exposing a tethered ligand (TL) that then auto-activates the re-
ceptor. In addition, a synthetic peptide corresponding to the TL (SLIGKV)
for PAR2 speciﬁcally activates PAR2 in the absence of proteases [22]. This
activating sequence of PAR2 could be found in the cystein-rich region of
DPP4 responsible for partner binding. We observed an almost perfect
match for the ﬁrst four amino acids, which aremost important for the ac-
tivation of PAR2 [1]. Within the tertiary structure of DPP4, the potential
PAR2 TL sequence SLIG could be located on the protein surface. It might
be speculated, that sDPP4 activates the PAR2 receptor with its TL se-
quence and that DPP4-inhibitors affect the binding properties of sDPP4
possibly by a conformational change. A similar phenomenon was ob-
served by Piazza and colleagues, who showed that enzymatic inhibition
of DPP4 affects its well known binding to ﬁbronectin [35]. Interestingly,
the binding site of ﬁbronectin and the potential PAR2 binding side are
both located in the cystein-rich regionofDPP4. Additionally, the sDPP4 in-
duced signaling in our cell model is consistent with the known PAR2 sig-
naling signature. In the literature it has already been shown that
stimulationwith the PAR2-AP leads to NF-κB [10] and ERK1/2 [26] activa-
tion resulting in SMC mitogenesis. Regarding the sDPP4 effects on cyto-
kine secretion, in human neutrophils, it could be shown that the PAR2-
AP induces IL-6 and IL-8 secretion [41]. Thus, our in vitro data indicate
that PAR2 is involved in the sDPP4-induced effects in hVSMC. Whether
sDPP4 directly binds to PAR2 and how the DPP4-inhibitormight interfere
with this potential binding requires further investigations.
5. Conclusion
In conclusion, in this study we characterized a novel sDPP4-induced
signaling cascade in hVSMC. sDPP4 directly and markedly activates the
MAPK- and NF-κB signaling pathway in a PAR2 dependent manner
leading to pro-atherogenic changes in hVSMC like increased prolifera-
tion and inﬂammation. The observed in vitro effects might also play a
role in vivo but would certainly coincide with the classical effects of
DPP4 to cleave and inactivate incretin hormones and other substrates.
Considering that sDPP4 is an adipokinewith increased circulating levels
in obesity, it can be speculated that sDPP4 may act in a para- or endo-
crine fashion on the vascular wall which could potentially contribute
to inﬂammation in this setting.
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